--- title: "XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald" description: "Cantor Fitzgerald has reduced its FY2025 EPS estimate for Xenon Pharmaceuticals (NASDAQ:XENE) from ($3.43) to ($3.85), while the consensus estimate stands at ($3.10). The firm also projected FY2026 EP" type: "news" locale: "en" url: "https://longbridge.com/en/news/253309566.md" published_at: "2025-08-16T13:14:41.000Z" --- # XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald > Cantor Fitzgerald has reduced its FY2025 EPS estimate for Xenon Pharmaceuticals (NASDAQ:XENE) from ($3.43) to ($3.85), while the consensus estimate stands at ($3.10). The firm also projected FY2026 EPS at ($4.08). Xenon reported a quarterly EPS of ($1.07), missing estimates. Several analysts have adjusted their price targets, with an average rating of "Moderate Buy" and a consensus target price of $53.20. The stock opened at $37.67, with a market cap of $2.90 billion and institutional ownership at 95.45%. - Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report released on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the biopharmaceutical company will earn ($3.85) per share for the year, down from their previous estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($4.08) EPS. Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm posted ($0.75) earnings per share. Get **Xenon Pharmaceuticals** alerts: Several other research firms have also recently weighed in on XENE. Needham & Company LLC dropped their price objective on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wells Fargo & Company dropped their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $53.20. **Get Our Latest Report on Xenon Pharmaceuticals** ## Xenon Pharmaceuticals Stock Performance NASDAQ XENE opened at $37.67 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $46.00. The stock has a 50 day simple moving average of $32.31 and a two-hundred day simple moving average of $34.09. The stock has a market cap of $2.90 billion, a P/E ratio of -10.61 and a beta of 1.16. ## Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently added to or reduced their stakes in XENE. Geode Capital Management LLC increased its position in Xenon Pharmaceuticals by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock valued at $2,726,000 after buying an additional 720 shares in the last quarter. Raymond James Financial Inc. bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $797,000. Barclays PLC increased its position in Xenon Pharmaceuticals by 20.9% during the 4th quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 3,134 shares in the last quarter. XTX Topco Ltd bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $316,000. Finally, Walleye Capital LLC increased its position in Xenon Pharmaceuticals by 111.5% during the 4th quarter. Walleye Capital LLC now owns 221,982 shares of the biopharmaceutical company's stock valued at $8,702,000 after buying an additional 117,022 shares in the last quarter. Institutional investors own 95.45% of the company's stock. ## Xenon Pharmaceuticals Company Profile (Get Free Report) Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. ## Read More - Five stocks we like better than Xenon Pharmaceuticals - REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today - Data Centers Create a Bull Case for These Nuclear 3 Stocks - What is the Nikkei 225 index? - Tesla’s Pennant Just Snapped: Here’s What It Means for the Stock - 5 Top Rated Dividend Stocks to Consider - 3 Companies That Will Profit From Trump's Semiconductor Tariffs *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Xenon Pharmaceuticals Right Now? Before you consider Xenon Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list. While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [XENE.US - Xenon Pharma](https://longbridge.com/en/quote/XENE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Xenon 製藥：被低估的 “藥物中的管線” 故事，具有重磅潛力，關鍵的 2026 年數據發佈在即 | 威廉·布萊爾分析師邁爾斯·敏特（Myles Minter）重申了對 Xenon Pharmaceuticals（XENE）的買入評級，指出其主要癲癇資產和更廣泛的產品線具有強大的潛力。他預計 2026 年 3 月的第三階段 X-TOLE2 | [Link](https://longbridge.com/en/news/272451525.md) | | Xenon 製藥在摩根大通醫療健康大會上展示其研發管線的最新進展 | Xenon Pharmaceuticals Inc. 在 2026 年摩根大通醫療健康大會上介紹了其臨牀管道的最新進展，重點關注其在癲癇和抑鬱症方面的三期臨牀試驗程序 azetukalner。該演講於 1 月 12 日上午 9:00（太平洋 | [Link](https://longbridge.com/en/news/272277538.md) | | 領先汽車配件的沉重債務負擔加劇了流動性、再融資以及業務扭轉的風險 | Advance Auto Parts Inc (AAP) 正面臨重大財務風險，主要由於其沉重的債務負擔，這可能限制流動性和融資渠道。這種情況可能迫使更多現金流用於償債，而非投資，從而增加對經濟衰退和潛在契約違約的脆弱性。在嚴峻的信貸環境中， | [Link](https://longbridge.com/en/news/275997122.md) | | 每千次展示 60 美元！OpenAI 用高價拉開 “AI 廣告” 大幕 | 為應對 AI 鉅額開支，OpenAI 正式測試廣告，CPM60 美元起步、最低投入 20 萬美元，定位高端渠道，直接挑戰谷歌萬億美元市場，WPP 等頂級代理已率先合作。但轉型風險並存：需平衡用户信任，承諾不用私聊數據；對手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) | | 華爾街對 AtaiBeckley（ATAI）持樂觀態度，原因如下 | 華爾街對 AtaiBeckley Inc.（納斯達克代碼：ATAI）持樂觀態度，認為其是一個潛力巨大的低價股，預計上漲空間超過 202%。H.C. Wainwright 的分析師 Patrick Trucchio 重新確認了該股票的買入評級 | [Link](https://longbridge.com/en/news/276000823.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.